News - dapagliflozin, Onglyza

Filter

Current filters:

dapagliflozinOnglyza

Popular Filters

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

AstraZeneca’s fixed-dose diabetes drug Xigduo approved in Europe

22-01-2014

The European Commission has approved Anglo-Swedish drug major AstraZeneca and soon to be ex-partner USA-based…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesPharmaceuticalRegulationXigduo

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

US FDA approves AstraZeneca’s Farxiga to treat type 2 diabetes

09-01-2014

Reversing a previous 2012 negative decision, the US Food and Drug Administration yesterday approved Anglo-Swedish…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesFarxigaNorth AmericaPharmaceuticalRegulationUSA

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

Strong FDA advisory panel backing for Bristol-Myers/AstraZeneca’s diabetes drug

13-12-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesForxigaNorth AmericaPharmaceuticalRegulation

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results

23-10-2013

Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

27-09-2013

Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular…

AstraZenecaBristol-Myers SquibbDiabetesOnglyzaPharmaceuticalResearch

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

AstraZeneca records fall in 2nd-qtr revenue but 21% rise in China sales

01-08-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reported second-quarter 2013 financial results with…

AstraZenecaBrilintaByettaEuropeFinancialOnglyzaPharmaceuticalSymbicort

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10-07-2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

AstraZeneca and Bristol-Myers get first approval for diabetes drug Forxiga

15-11-2012

There was good news for AstraZeneca (LSE: AZN) and Bristol-Myers Squibb (NYSE: BMY), with the European…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesEuropeForxigaPharmaceuticalRegulation

FDA’s CRL on dapagliflozin calls for more clinical data

19-01-2012

In what comes as no surprise given a negative vote by an Food and Drug Administration advisory panel…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

EC approves additional use for Bristol-Myers and AstraZeneca’s Onglyza and Komboglyze

29-11-2011

The European Commission has approved drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca’s…

AstraZenecaBristol-Myers SquibbDiabetesEuropeKomboglyzeOnglyzaPharmaceuticalResearch

AstraZeneca and B-MS see delay for dapagliflozin, as AZ posts 3rd-qtr 2011 results with generics taking a toll

27-10-2011

Just as Anglo-Swedish drug major AstraZeneca (LSE: AZN) was about to announce third-quarter 2011 financial…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesFinancialPharmaceuticalRegulation

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015

13-10-2011

Russia’s type 2 diabetes drug market will grow more than seven percent annually from $1.2 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesEuropeJohnson & JohnsonMarkets & MarketingPharmaceutical

US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues

20-07-2011

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

Highlights from American Diabetes Association meeting

27-06-2011

There was a batch of good news coming out of the American Diabetes Association (ADA) 71st annual scientific…

ApidraAstraZenecaBristol-Myers SquibbdapagliflozinDiabetesLantusLyxumiaNovo NordiskOnglyzaPharmaceuticalResearchSanofiVictoza

Company Spotlight

Fibrotech

Fibrotech

Back to top